TVTX Stock: Price, Earnings History and SEC Filings
Travere Therapeutics, Inc. (TVTX) last traded at $50.39, down 0.36% on the latest session and down 14.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.37 against an analyst estimate of $-0.14, a miss of 164.3%.
$50.39 -0.36%
1 month-14.42%
52-week high$68.73
52-week low$22.59
Volume1.14M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TVTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 4, 2026 | $-0.37 | $-0.14 | -164.29% |
| Mar 2026 | May 4, 2026 | $-0.39 | $-0.30 | -30.00% |
| Dec 2025 | Feb 19, 2026 | $0.03 | $0.03 | +0.00% |
| Sep 2025 | Oct 30, 2025 | $0.28 | $-0.31 | +190.32% |
TVTX beat the analyst EPS estimate in 1 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for TVTX
SEC filing data is not available right now. You can search for TVTX on SEC EDGAR.
TVTX news
- Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue EstimatesOct 28, 2026 · finance.yahoo.com
- Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?Oct 28, 2026 · finance.yahoo.com
- Travere Therapeutics to Report Third Quarter 2026 Financial ResultsOct 26, 2026 · finance.yahoo.com
- Travere Presents New Biomarker Data at ASN Kidney Week Suggesting FILSPARI® (sparsentan) May Modify Underlying Disease Pathophysiology in IgA NephropathyOct 23, 2026 · finance.yahoo.com
- AstraZeneca Gets Accelerated FDA Nod for Ultomiris in IgA NephropathyOct 22, 2026 · finance.yahoo.com
- Earnings Preview: Travere Therapeutics (TVTX) Q3 Earnings Expected to DeclineOct 22, 2026 · finance.yahoo.com
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc. (TVTX) is a US-listed public company on Nasdaq.